Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-arm, Open-Label, Multicenter Phase II Clinical Study to Evaluate Efficacy and Safety of HLX07 (Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) in Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)

Trial Profile

A Single-arm, Open-Label, Multicenter Phase II Clinical Study to Evaluate Efficacy and Safety of HLX07 (Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) in Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pimurutamab (Primary)
  • Indications Carcinoma; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors Shanghai Henlius Biotech

Most Recent Events

  • 05 Dec 2023 According to a Henlius Biopharmaceuticals media release, results from this study were presented at the European Society for Medical Oncology Asia (ESMO Asia) Congress 2023.
  • 05 Dec 2023 Results ( N=31, Cut of 2 July 2023) presented in a Henlius Biopharmaceuticals media release.
  • 09 Jun 2022 Planned initiation date changed from 19 May 2022 to 19 Jun 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top